Literature DB >> 32015032

Rezafungin In Vitro Activity against Contemporary Nordic Clinical Candida Isolates and Candida auris Determined by the EUCAST Reference Method.

Marie Helleberg1,2, Karin Meinike Jørgensen2, Rasmus Krøger Hare2, Raluca Datcu2, Anuradha Chowdhary3, Maiken Cavling Arendrup4,5,6.   

Abstract

Rezafungin (formerly CD101) is a novel echinocandin in clinical development. EUCAST epidemiological cutoff values (ECOFFs) have not yet been established. We determined the in vitro activity of rezafungin and comparators against 1,293 Nordic yeast isolates and 122 Indian Candida auris isolates and established single-center wild-type upper limits (WT-UL). The isolates (19 Candida spp. and 13 other yeast species) were identified using Chromagar; matrix-assisted laser desorption ionization-time of flight (MALDI-TOF); and, when needed, internal transcribed spacer sequencing. EUCAST E.Def 7.3.1 susceptibility testing included rezafungin, anidulafungin, micafungin, amphotericin B, and fluconazole. WT-UL were established following EUCAST principles for visual and statistical ECOFF setting. fks target genes were sequenced for rezafungin non-wild-type isolates. EUCAST clinical breakpoints for fungi version 9.0 were adopted for susceptibility classification. Rezafungin had species-specific activity similar to that of anidulafungin and micafungin. On a milligram-per-liter basis, rezafungin was overall less active than anidulafungin and micafungin but equally or more active than fluconazole and amphotericin B against the most common Candida species, except C. parapsilosis We identified 37 (3.1%) rezafungin non-wild-type isolates of C. albicans (1.9%), C. glabrata (3.0%), C. tropicalis (2.7%), C. dubliniensis (2.9%), C. krusei (1.2%), and C. auris (14.8%). Alterations in Fks hot spots were found in 26/26 Nordic and 8/18 non-wild-type C. auris isolates. Rezafungin displayed broad in vitro activity against Candida spp., including C. auris Adopting WT-UL established here, few Nordic strains, but a significant proportion of C. auris isolates, had elevated MICs with mutations in fks target genes that conferred echinocandin cross-resistance. fks1 mutations raised rezafungin MICs notably less than anidulafungin and micafungin MICs in C. auris.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Candida; Candida auris; EUCAST; MIC; antifungal resistance; antifungal susceptibility testing; echinocandin; in vitro activity; rezafungin

Year:  2020        PMID: 32015032      PMCID: PMC7179313          DOI: 10.1128/AAC.02438-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents.

Authors:  M C Arendrup; J Meletiadis; J W Mouton; J Guinea; M Cuenca-Estrella; K Lagrou; S J Howard
Journal:  Clin Microbiol Infect       Date:  2016-02-03       Impact factor: 8.067

2.  Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?

Authors:  A Espinel-Ingroff; M C Arendrup; M A Pfaller; L X Bonfietti; B Bustamante; E Canton; E Chryssanthou; M Cuenca-Estrella; E Dannaoui; A Fothergill; J Fuller; P Gaustad; G M Gonzalez; J Guarro; C Lass-Flörl; S R Lockhart; J F Meis; C B Moore; L Ostrosky-Zeichner; T Pelaez; S R B S Pukinskas; G St-Germain; M W Szeszs; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

3.  CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program.

Authors:  Michael A Pfaller; Shawn A Messer; Paul R Rhomberg; Mariana Castanheira
Journal:  Int J Antimicrob Agents       Date:  2017-07-06       Impact factor: 5.283

4.  Role of FKS Gene in the Susceptibility of Pathogenic Fungi to Echinocandins.

Authors:  Yasuhiro Hori; Kazutoshi Shibuya
Journal:  Med Mycol J       Date:  2018

5.  Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method.

Authors:  M C Arendrup; J Meletiadis; O Zaragoza; K M Jørgensen; L J Marcos-Zambrano; L Kanioura; M Cuenca-Estrella; J W Mouton; J Guinea
Journal:  Clin Microbiol Infect       Date:  2018-03-02       Impact factor: 8.067

6.  Echinocandin susceptibility testing of Candida spp. Using EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: analysis of the influence of bovine serum albumin supplementation, storage time, and drug lots.

Authors:  Maiken Cavling Arendrup; Juan-Luis Rodriguez-Tudela; Steven Park; Guillermo Garcia-Effron; Guillaume Delmas; Manuel Cuenca-Estrella; Alicia Gomez-Lopez; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2011-01-18       Impact factor: 5.191

Review 7.  Echinocandin resistance: an emerging clinical problem?

Authors:  Maiken C Arendrup; David S Perlin
Journal:  Curr Opin Infect Dis       Date:  2014-12       Impact factor: 4.915

8.  APX001A In Vitro Activity against Contemporary Blood Isolates and Candida auris Determined by the EUCAST Reference Method.

Authors:  Maiken Cavling Arendrup; Anuradha Chowdhary; Karen M T Astvad; Karin Meinike Jørgensen
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

9.  Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults.

Authors:  Taylor Sandison; Voon Ong; Jonathan Lee; Dirk Thye
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

10.  Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata.

Authors:  Justin C Bader; Elizabeth A Lakota; Shawn Flanagan; Voon Ong; Taylor Sandison; Christopher M Rubino; Sujata M Bhavnani; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

View more
  11 in total

Review 1.  Emerging and future strategies in the management of recalcitrant Candida auris.

Authors:  Nihal Bandara; Lakshman Samaranayake
Journal:  Med Mycol       Date:  2022-03-17       Impact factor: 4.076

Review 2.  Candida auris, a singular emergent pathogenic yeast: its resistance and new therapeutic alternatives.

Authors:  Liliana Fernandes; Rita Ribeiro; Mariana Henriques; Maria Elisa Rodrigues
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-10-06       Impact factor: 5.103

3.  Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action.

Authors:  Martin Hoenigl; Rosanne Sprute; Amir Arastehfar; John R Perfect; Cornelia Lass-Flörl; Romuald Bellmann; Juergen Prattes; George R Thompson; Nathan P Wiederhold; Mohanad M Al Obaidi; Birgit Willinger; Maiken C Arendrup; Philipp Koehler; Matteo Oliverio; Matthias Egger; Ilan S Schwartz; Oliver A Cornely; Peter G Pappas; Robert Krause
Journal:  Expert Opin Investig Drugs       Date:  2022-06-15       Impact factor: 6.498

Review 4.  Antifungal Resistance among Less Prevalent Candida Non-albicans and Other Yeasts versus Established and under Development Agents: A Literature Review.

Authors:  Ana Espinel-Ingroff; Emilia Cantón; Javier Pemán
Journal:  J Fungi (Basel)       Date:  2021-01-04

Review 5.  The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.

Authors:  Martin Hoenigl; Rosanne Sprute; Matthias Egger; Amir Arastehfar; Oliver A Cornely; Robert Krause; Cornelia Lass-Flörl; Juergen Prattes; Andrej Spec; George R Thompson; Nathan Wiederhold; Jeffrey D Jenks
Journal:  Drugs       Date:  2021-10-09       Impact factor: 9.546

Review 6.  A Pragmatic Approach to Susceptibility Classification of Yeasts without EUCAST Clinical Breakpoints.

Authors:  Karen Marie Thyssen Astvad; Sevtap Arikan-Akdagli; Maiken Cavling Arendrup
Journal:  J Fungi (Basel)       Date:  2022-01-30

Review 7.  Candidemia: Evolution of Drug Resistance and Novel Therapeutic Approaches.

Authors:  Anna Maria Tortorano; Anna Prigitano; Gianluca Morroni; Lucia Brescini; Francesco Barchiesi
Journal:  Infect Drug Resist       Date:  2021-12-19       Impact factor: 4.003

Review 8.  Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications.

Authors:  Thomas R Rogers; Paul E Verweij; Mariana Castanheira; Eric Dannaoui; P Lewis White; Maiken Cavling Arendrup
Journal:  J Antimicrob Chemother       Date:  2022-07-28       Impact factor: 5.758

Review 9.  Investigational Agents for the Treatment of Resistant Yeasts and Molds.

Authors:  Garret T Seiler; Luis Ostrosky-Zeichner
Journal:  Curr Fungal Infect Rep       Date:  2021-05-28

Review 10.  Promising Drug Candidates and New Strategies for Fighting against the Emerging Superbug Candida auris.

Authors:  Muriel Billamboz; Zeeshan Fatima; Saif Hameed; Samir Jawhara
Journal:  Microorganisms       Date:  2021-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.